|
1
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Australian Ovarian Cancer Study Group: Whole-genome
characterization of chemoresistant ovarian cancer. Nature.
521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj
A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E,
Cruickshank D, et al: Ovarian cancer screening and mortality in the
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A
randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anborgh PH, Mutrie JC, Tuck AB and
Chambers AF: Pre- and post-translational regulation of osteopontin
in cancer. J Cell Commun Signal. 5:111–122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ue T, Yokozaki H, Kitadai Y, Yamamoto S,
Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and
CD44v9 in gastric cancer. Int J Cancer. 79:127–132. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agrawal D, Chen T, Irby R, Quackenbush J,
Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ:
Osteopontin identified as lead marker of colon cancer progression,
using pooled sample expression profiling. J Natl Cancer Inst.
94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weber GF: The metastasis gene osteopontin:
A candidate target for cancer therapy. Biochim Biophys Acta.
1552:61–85. 2001.PubMed/NCBI
|
|
7
|
Rudland PS, Platt-Higgins A, El-Tanani M,
De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R and West
CR: Prognostic significance of the metastasis-associated protein
osteopontin in human breast cancer. Cancer Res. 62:3417–3427.
2002.PubMed/NCBI
|
|
8
|
Thalmann GN, Sikes RA, Devoll RE, Kiefer
JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE and Chung
LW: Osteopontin: Possible role in prostate cancer progression. Clin
Cancer Res. 5:2271–2277. 1999.PubMed/NCBI
|
|
9
|
Chambers AF, Wilson SM, Kerkvliet N,
O'Malley FP, Harris JF and Casson AG: Osteopontin expression in
lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodrigues LR, Teixeira JA, Schmitt FL,
Paulsson M and Lindmark-Mänsson H: The role of osteopontin in tumor
progression and metastasis in breast cancer. Cancer Epidemiol
Biomarkers Prev. 16:1087–1097. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeatman TJ and Chambers AF: Osteopontin
and colon cancer progression. Clin Exp Metastasis. 20:85–90. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Donati V, Boldrini L, Dell'Omodarme M,
Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M,
Basolo F, et al: Osteopontin expression and prognostic significance
in non-small cell lung cancer. Clin Cancer Res. 11:6459–6465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khodavirdi AC, Song Z, Yang S, Zhong C,
Wang S, Wu H, Pritchard C, Nelson PS and Roy-Burman P: Increased
expression of osteopontin contributes to the progression of
prostate cancer. Cancer Res. 66:883–888. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He B, Mirza M and Weber GF: An osteopontin
splice variant induces anchorage independence in human breast
cancer cells. Oncogene. 25:2192–2202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katagiri YU, Sleeman J, Fujii H, Herrlich
P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M,
et al: CD44 variants but not CD44s cooperate with beta1-containing
integrins to permit cells to bind to osteopontin independently of
arginine-glycine-aspartic acid, thereby stimulating cell motility
and chemotaxis. Cancer Res. 59:219–226. 1999.PubMed/NCBI
|
|
16
|
Liu H, Chen A, Guo F and Yuan L: A
short-hairpin RNA targeting osteopontin downregulates MMP-2 and
MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett.
295:27–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buommino E, De Filippis A, Gaudiello F,
Balato A, Balato N, Tufano MA and Ayala F: Modification of
osteopontin and MMP-9 levels in patients with psoriasis on
anti-TNF-α therapy. Arch Dermatol Res. 304:481–485. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Desai B, Rogers MJ and Chellaiah MA:
Mechanisms of osteopontin and CD44 as metastatic principles in
prostate cancer cells. Mol Cancer. 6:182007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gotoh M, Sakamoto M, Kanetaka K, Chuuma M
and Hirohashi S: Overexpression of osteopontin in hepatocellular
carcinoma. Pathol Int. 52:19–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong M, Lu Z, Fang G, Bi J and Xue X: A
small interfering RNA targeting osteopontin as gastric cancer
therapeutics. Cancer Lett. 272:148–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
